Kenvue Inc. (NYSE:KVUE) Stock Holdings Lowered by Modus Advisors LLC

Modus Advisors LLC lowered its position in shares of Kenvue Inc. (NYSE:KVUE) by 5.5% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 105,897 shares of the company’s stock after selling 6,198 shares during the period. Modus Advisors LLC’s holdings in Kenvue were worth $2,539,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Geneos Wealth Management Inc. acquired a new position in Kenvue during the 4th quarter valued at about $29,000. SRS Capital Advisors Inc. increased its stake in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after buying an additional 571 shares during the period. Asset Planning Inc acquired a new position in Kenvue during the 4th quarter valued at about $42,000. Clarity Asset Management Inc. acquired a new position in Kenvue during the 4th quarter valued at about $45,000. Finally, SBI Securities Co. Ltd. acquired a new position in Kenvue during the 4th quarter valued at about $46,000. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on KVUE. Canaccord Genuity Group raised their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Piper Sandler raised their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. UBS Group raised their price objective on shares of Kenvue from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Friday, May 9th. Finally, Redburn Atlantic initiated coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a “neutral” rating and a $23.50 price objective for the company. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $25.33.

Kenvue Stock Performance

Shares of KVUE opened at $23.55 on Thursday. Kenvue Inc. has a one year low of $17.67 and a one year high of $25.17. The company has a 50-day moving average of $23.25 and a two-hundred day moving average of $22.64. The stock has a market cap of $45.19 billion, a price-to-earnings ratio of 44.43, a PEG ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The company had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. During the same period last year, the company posted $0.28 earnings per share. The business’s revenue for the quarter was down 3.9% on a year-over-year basis. On average, equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.48%. The ex-dividend date was Wednesday, May 14th. Kenvue’s payout ratio is 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.